Research Trials

We are currently enrolling for one of our glaucoma trials. If you have Ocular Hypertension or Primary Open Angle Glaucoma and are interested in being off of eye drops, please ask our study coordinator for more information. 708-898-1858

OTX-TP is a preservative free drug product that is inserted into the canaliculus and is designed to deliver the prostaglandin analog travaprost to the ocular surface for up to 90 days. OTX-TP is designed to deliver a continuous steady release throughout the treatment period.

Caution: NEW DRUG- OTX-TP is currently undergoing evaluation in the Unites States and is limited by the United States law to investigational use only. This product has not been approved by the FDA as safe or effective.